全文获取类型
收费全文 | 4870篇 |
免费 | 216篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 181篇 |
妇产科学 | 10篇 |
基础医学 | 694篇 |
口腔科学 | 120篇 |
临床医学 | 295篇 |
内科学 | 1549篇 |
皮肤病学 | 38篇 |
神经病学 | 336篇 |
特种医学 | 165篇 |
外科学 | 702篇 |
综合类 | 9篇 |
预防医学 | 116篇 |
眼科学 | 43篇 |
药学 | 313篇 |
中国医学 | 13篇 |
肿瘤学 | 508篇 |
出版年
2023年 | 15篇 |
2022年 | 37篇 |
2021年 | 82篇 |
2020年 | 47篇 |
2019年 | 46篇 |
2018年 | 63篇 |
2017年 | 49篇 |
2016年 | 70篇 |
2015年 | 82篇 |
2014年 | 131篇 |
2013年 | 154篇 |
2012年 | 292篇 |
2011年 | 303篇 |
2010年 | 146篇 |
2009年 | 136篇 |
2008年 | 291篇 |
2007年 | 316篇 |
2006年 | 337篇 |
2005年 | 315篇 |
2004年 | 379篇 |
2003年 | 391篇 |
2002年 | 367篇 |
2001年 | 54篇 |
2000年 | 49篇 |
1999年 | 76篇 |
1998年 | 90篇 |
1997年 | 88篇 |
1996年 | 94篇 |
1995年 | 51篇 |
1994年 | 79篇 |
1993年 | 63篇 |
1992年 | 49篇 |
1991年 | 52篇 |
1990年 | 34篇 |
1989年 | 36篇 |
1988年 | 31篇 |
1987年 | 21篇 |
1986年 | 26篇 |
1985年 | 17篇 |
1984年 | 30篇 |
1983年 | 14篇 |
1982年 | 11篇 |
1981年 | 19篇 |
1980年 | 16篇 |
1979年 | 11篇 |
1978年 | 20篇 |
1977年 | 7篇 |
1976年 | 11篇 |
1975年 | 5篇 |
1973年 | 5篇 |
排序方式: 共有5119条查询结果,搜索用时 31 毫秒
81.
Penetration of etoposide into human malignant brain tumors after intravenous and oral administration
Katsuzo Kiya Tohru Uozumi Hidenori Ogasawara Kazuhiko Sugiyama Takuhiro Hotta Takashi Mikami Kaoru Kurisu 《Cancer chemotherapy and pharmacology》1992,29(5):339-342
Summary Penetration of etoposide into the cerebrospinal fluid, brain tumor, and brain tissue after intravenous administration was investigated in patients presenting with malignant brain tumors. A relatively low dose (55–65 mg/m2) was used to compare intravenous with oral administration. High-performance liquid chromatography with fluorescence detection was used to evaluate drug levels. Plasma and cerebrospinal fluid levels of etoposide after oral administration (50–150 mg/day) were also studied so as to determine the adequate oral dose for the treatment of malignant brain tumors. The peak plasma concentration after intravenous administration ranged from 7.01 to 10.47 g/ml, varying in proportion to the injected dose, whereas that after oral administration was lower, namely, 1.44–4.99 g/ml, and was unstable when the oral dose was 150 mg daily. The peak cerebrospinal fluid level following either intravenous or oral administration was much lower than the plasma concentration and was influenced by the peak plasma level and the sampling site. The etoposide concentration in cerebrospinal fluid taken from the subarachnoid space and ventricle of patients displaying no tumor invasion and of those presenting with meningeal carcinomatosis and in cerebrospinal fluid taken from the dead space after tumor resection was 0.7%±0.5%, 3.4%±1.0%, and 7.2% ± 8.5%, respectively, of the plasma concentration. Serial oral administration did not result in the accumulation of etoposide in cerebrospinal fluid. The tumor concentration (1.04–4.80 g/g) was 14.0%±2.9% of the plasma level after intravenous administration, was related to the injected dose, and was approximately twice the concentration detected in the brain tissue. Therefore, a relatively low dose of etoposide injected intravenously penetrates the brain tumor at an efficacious concentration. Our results indicate than an oral dose of 100 mg etoposide be given for malignant brain tumors, as limited penetration of the drug into the intracranial region was observed. 相似文献
82.
Akio Kanetoshi Eiji Katsura Hiroshi Ogawa Tohru Ohyama Hiroyasu Kaneshima Toshiaki Miura 《Archives of environmental contamination and toxicology》1992,23(1):91-98
Acute toxicity of 2,4,4-trichloro-2-hydroxydiphenyl ether (Irgasan® DP300) (I) and its three chlorinated derivatives, 2,3,4,4-tetrachloro-2-hydroxydiphenyl ether (II), 2,4,4,5-tetrachloro-2-hydroxydiphenyl ether (III) and 2,3,4,4,5-pentachloro-2-hydroxydiphenyl ether (IV), in mice were examined by intraperitoneal injection. The LD50 values of Irgasan DP300, II, III and IV were 1,090, 710, 650 and 430 mg/kg, respectively.The percutaneous absorptions of these tritiated compounds were also examined by the application on the backs of mice. The radioactivities in most tissues reached to the maximal levels at 12 h or 18 h after dosing, which corresponded to 11–76% of the maximal levels given by the oral administration (Kanetoshi et al. 1988a). These results show the high percutaneous absorbability of Irgasan DP300 and its chlorinated derivatives.The intraperitoneal administrations of III and IV to rats induced hepatic microsomal aminopyrine N-demethylase and aniline 4-hydroxylase activities similarly to phenobarbital. These chlorinated derivatives also increased cytochrome P-450 content, and the activities of aminopyrine N-demethylase and N-methylaniline N-demethylase in hepatic microsomes from mice. The extents of the increases were similar to those by phenobarbital and 3-methylcholanthrene. 相似文献
83.
Key words airway management - difficult intubation - Hallermann-Streiff syndrome 相似文献
84.
85.
86.
87.
88.
89.
Toshiharu Miyake Tohru Shinohara Yoshihide Nakamura Tsuyoshi Fukuda Hiroshi Tasato Keiko Toyohara Yuko Tanihira 《Pediatrics international》2004,46(2):135-140
BACKGROUND: This study evaluates the incidence and timing of spontaneous closure (SC) of ventricular septal defect (VSD) using Doppler color flow mapping. METHODS: A total of 225 infants (mean age 30 days) were diagnosed with uncomplicated VSD: 31 (14%) subpulmonary VSD, 159 (70%) perimembranous, and 35 (16%) muscular. The patients were divided into two groups according to the presence or absence of congestive heart failure (CHF). SC was confirmed with color Doppler. RESULTS: Surgical closure was performed in 59 patients (26%). SC occurred in 107 patients (48%); three (10%) of 31 with subpulmonary VSD, 75 (47%) of 159 with perimembranous VSD, and 29 (83%) of 35 with a muscular VSD. Average age at SC was 19 months. In three SC patients with a subpulmonary VSD, there was no aortic valve prolapse and no aortic regurgitation. SC occurred in 96% of SC patients with a perimembranous VSD by the age of 6 years, and in 93% of those with a muscular VSD by the age of 3 years. In patients without CHF, the rate of SC was 72%; 23% in subpulmonary VSD, 74% in perimembranous, and 85% in muscular. SC occurred in only 23% of patients with a perimembranous VSD with CHF. Mean age at the final examination was 6.9 years in 59 patients with a VSD remaining open, and 63% of patients with a perimembranous VSD remaining open had an aneurysm of the ventricular membranous septum. CONCLUSIONS: The SC rate of VSD by mean age of 6.9 years was 48%, but it was 72% in patients without CHF. In patients with CHF, SC was seen only in patients with a perimembranous VSD. The rate of SC was 10% in subpulmonary VSD. The authors contend that SC probably occurred by growth of muscular septum surrounding VSD. Muscular VSD spontaneously closed earlier than perimembranous VSD. 相似文献
90.
Hisashi Nagahara Koshi Mimori Mitsuhiko Ohta Tohru Utsunomiya Hiroshi Inoue Graham F Barnard Masaichi Ohira Kosei Hirakawa Masaki Mori 《Clinical cancer research》2005,11(4):1368-1371
PURPOSE: Somatic mutations of the epidermal growth factor receptor (EGFR) gene may predict the sensitivity of non-small cell lung carcinoma to gefitinib. However, no mutations have been reported for colorectal carcinoma. We therefore analyzed EGFR mutations in colorectal adenocarcinomas by the combined use of laser microdissection and sequencing of genomic DNA. EXPERIMENTAL DESIGN: We examined 11 representative colorectal adenocarcinoma cell lines and 33 clinical samples of colorectal carcinoma. In the clinical cases, we carefully dissected only carcinoma cells from frozen sections by laser microdissection. After DNA extraction and PCR, we examined EGFR mutations by sequencing genomic DNA. RESULTS: None of 11 colorectal carcinoma cell lines exhibited somatic mutations, but 4 of 33 clinical tumors (12%) exhibited mutations in the EGFR kinase domain. This may be the first report of somatic mutations in colorectal adenocarcinoma. CONCLUSIONS: Our findings suggest that a distinct minority of colorectal adenocarcinomas exhibit somatic mutations of EGFR, and these tumors may be susceptible to gefitinib treatment. 相似文献